Hémorragie survenant chez un patient traité par un anticoagulant oral direct

Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 Godier, 2015, Gestion des anticoagulants oraux directs pour un acte invasif, J Mal Vasc, 40, 173, 10.1016/j.jmv.2015.02.004 Marlu, 2012, Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers, Thromb Haemost, 108, 217, 10.1160/TH12-03-0179 Lee, 2014, Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies, Thromb Res, 133, 705, 10.1016/j.thromres.2014.01.031 Zahir, 2015, Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate, Circulation, 131, 82, 10.1161/CIRCULATIONAHA.114.013445 Levi, 2010, Safety of recombinant activated factor VII in randomized clinical trials, N Engl J Med, 363, 1791, 10.1056/NEJMoa1006221 Pernod, 2014, Gihp-Naco prospective registry: characterization and care of major bleeding in patients treated by direct oral anticoagulants Glund, 2015, A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran, Thromb Haemost, 113, 943, 10.1160/TH14-12-1080 Pollack, 2015, Idarucizumab for dabigatran reversal, N Engl J Med, 373, 511, 10.1056/NEJMoa1502000 Grottke, 2015, Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation, J Am Coll Cardiol, 66, 1518, 10.1016/j.jacc.2015.07.051 Siegal, 2015, Andexanet alfa for the reversal of factor Xa inhibitor activity, N Engl J Med, 373, 2413, 10.1056/NEJMoa1510991 Ansell, 2014, Use of PER977 to reverse the anticoagulant effect of edoxaban, N Engl J Med, 371, 2141, 10.1056/NEJMc1411800 Pernod, 2013, [Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013], Ann Fr Anesth Reanim, 32, 691, 10.1016/j.annfar.2013.04.016 Godier, 2015, Peri-procedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations, Thromb Res, 136, 763, 10.1016/j.thromres.2015.08.006 Gouin-Thibault, 2014, Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study, Thromb Haemost, 111, 240, 10.1160/TH13-06-0470 2008 Pernod, 2013, Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013, Arch Cardiovasc Dis, 106, 382, 10.1016/j.acvd.2013.04.009 Kozek-Langenecker, 2013, Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology, Eur J Anaesthesiol, 30, 270, 10.1097/EJA.0b013e32835f4d5b Spahn, 2013, Management of bleeding and coagulopathy following major trauma: an updated European guideline, Crit Care, 17, R76, 10.1186/cc12685